FDAapproval72% confidence
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
Source: FDA
Why This Matters
Why this matters: sets a approval precedent in the same sub-indication (melanoma) as Immunocore.
Regulatory Analysis
FDA does not issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to Drugs@FDA for the latest approvals and prescribing information for specific products.
Supporting Context
- Therapeutic area
- Oncology · Immune-Mobilizing T-cell Receptors
- Sub-indication
- Melanoma
Related signal: Tebentafusp establishes first-line treatment for HLA-A*02:01-positive uveal melanoma